Gerald T. Proehl

Gerald T. Proehl is a declared insider at 6 companies (chief executive); the most frequent names are Santarus Inc, Dermata Therapeutics, Inc. and Tenax Therapeutics, Inc. Over a trading history stretching from 15 March 2006 to 16 August 2026, the count stands at 162 filings.

In open-market terms, that means 21 purchases worth €488k on one side and 101 sales worth €9.1M on the other. The amount is not disclosed for 2 filings. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Outside the open market, there are 13 share grants and 11 option exercises.

A typical purchase (the median) is worth €9,681. None of the 5 purchases we analysed coincided with buying by another insider of the same company within 30 days.

The record was last updated on 18 August 2026 with a share grant in Dermata Therapeutics, Inc. The most recent open-market purchase was published on 8 August 2024, 807 days ago. The median gap between a trade and its publication by SEC (Form 4) is 1 day. Section 16 rules allow two business days to file each Form 4. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.